SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-058669
Filing Date
2024-05-13
Accepted
2024-05-13 16:15:31
Documents
57
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fbrx-20240331.htm   iXBRL 10-Q 1502515
2 EX-10.1 fbrx-ex10_1.htm EX-10.1 100214
3 EX-31.1 fbrx-ex31_1.htm EX-31.1 15144
4 EX-31.2 fbrx-ex31_2.htm EX-31.2 14861
5 EX-32.1 fbrx-ex32_1.htm EX-32.1 8760
6 EX-32.2 fbrx-ex32_2.htm EX-32.2 8825
  Complete submission text file 0000950170-24-058669.txt   6211973

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fbrx-20240331.xsd EX-101.SCH 952933
61 EXTRACTED XBRL INSTANCE DOCUMENT fbrx-20240331_htm.xml XML 910041
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38052 | Film No.: 24939257
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)